Pharmacyclics Inc (PCYC)

pos +0.87
Today's Range: 90.15 - 94.88 | PCYC Avg Daily Volume: 1,374,300
Last Update: 04/24/14 - 4:00 PM EDT
Volume: 1,351,645
YTD Performance: -11.51%
Open: $94.33
Previous Close: $93.61
52 Week Range: $74.36 - $154.89
Oustanding Shares: 74,788,370
Market Cap: 7,005,092,653
6-Month Chart
TheStreet Ratings Grade for PCYC
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 10 10 10
Moderate Buy 1 1 1 1
Hold 5 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.69 1.60 1.60 1.60
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 139.45
Price Earnings Comparisons:
PCYC Sector Avg. S&P 500
139.45 107.40 29.23
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-33.46% 13.81% 1,473.28%
Revenue 61.90 26.95 2.00
Net Income -43.00 -5.46 0.00
EPS -45.00 -3.97 0.00
Earnings for PCYC:
Revenue 0.26B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $0.03 $-0.39 $-0.70 $-0.54
Number of Analysts 8 8 11 10
High Estimate $0.31 $0.02 $1.27 $2.52
Low Estimate $-0.20 $-1.00 $-3.22 $-4.03
Prior Year $-0.73 $0.17 $0.87 $-0.70
Growth Rate (Year over Year) 103.94% -327.94% -180.25% 22.66%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
For these names, targets have climbed ahead of earnings releases.
These growth stocks are no longer an anchor to this market.
Nov 14, 2013 | 8:05 AM EST
PCYC was removed from the Best Ideas list, Wedbush said. Patient assistance programs for Imbruvica will be restricted.
Skittish buyers are only nibbling and leaving plenty of good cheap stocks for you.
Oct 11, 2013 | 7:37 AM EDT
PCYC was upgraded from Neutral to Buy, Goldman Sachs said. $170 price target. ibruttinib could generate $7.5 billion of peak annual sal...
This trend is a good indication that business is going well.
Sep 26, 2013 | 8:12 AM EDT
PCYC was initiated with an Overweight rating, JP Morgan said.J&J partnership should drive growth. 
Sep 04, 2013 | 7:32 AM EDT
PCYC was upgraded to Buy, Lazard Capital Markets said. $141 price target. Checks show a strong outlook for ibrutinib.
Feb 15, 2013 | 7:43 AM EST
Shares of PCYC now seen reaching $90, accoridng to Credit Suisse. Estimates also increased, as Ibrutinib should drive growth. Outperfor...
Jan 15, 2013 | 8:07 AM EST
Shares of PCYC rated new Outperform, Credit Suisse said. $79 price target. Most derisked pure play in oral lymphoma/leukemia drug class...

Columnist Conversations

CH Robinson has had a higher gap opening the last four days in a row. Boy, someone really wants to own it (see...
The wicked, whipsaw action following FB's earnings release last evening warns me the stock likely has ended a ...
This stock has been a dog for years, but its ears are perking here lately, and today has my eye. The May call...
Good afternoon! Oil has taken a swift turn this week and is showing further weakness ahead. Here is a quick up...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.